Page 6 - Gene Therapy Program News Today

Operator: Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode.

Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy ultra-rare disease program - FDA... | January 31, 2023

20.01.2023 - PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted ...

Item 2.02 Results of Operations and Financial Condition. On January 9, 2023, Precision BioSciences, Inc. issued a press release announcing its preliminary unaudited cash balance as of December 31,... | January 9, 2023

Taysha Gene Therapies Announces Executive Leadership Changes - read this article along with other careers information, tips and advice on BioSpace

Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of...

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna...

BioPharma

DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company...

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Tayshas...